FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2 Tyrosine Kinase Domain Activating Mutations By Ogkologos - August 29, 2025 671 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Beamion LUNG-1 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Benefit of Adjuvant Chemotherapy in Patients with ctDNA-positive Resected Stage II... July 30, 2026 Tisagenlecleucel Is Safe and Effective in Pretreated Patients with Relapsed/Refractory Follicular... December 21, 2021 seven Interesting Facts about Malignant tumors Boy Between the sheets July 20, 2023 Deputy Spends His Days Off Teaching Life Skills To Young Boys... December 26, 2021 Load more HOT NEWS EMA Recommends Extension of Indications for Alectinib to Adjuvant Treatment of... Drug Combination May Target the Unique Metabolism of Leukemia Stem Cells Even If Insured, People with Advanced Cancer Often Face Financial Problems Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in...
